相关实验视频

Updated: Jan 10, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

预测化合物与人类β1-adrenoceptor的2种已知激素诱导形状相互作用

Jillian G Baker¹, Victor Jun Yu Lim², Richard G W Proudman³

¹Cell Signalling, School of Life Sciences, C Floor Medical School, Queen's Medical Centre, University of Nottingham, Nottingham, UK; Respiratory Medicine, Sherwood Forest Hospitals NHS Trust, King's Mill Hospital, Nottinghamshire, UK; Respiratory Medicine, Nottingham University NHS Trust, Queen's Medical Centre, Nottingham, UK.

Molecular pharmacology

|November 25, 2025

概括

β1-上腺受体有两个主要构造,由不同的配体激活. 这项研究确定了替代构造的特定相互作用点,并发现了激活它的新型化合物,提供了新的分子洞察力.

科学领域:

药理学药理学是指药理学的学科.
分子生物学分子生物学
生物化学生物化学

背景情况:

β1-上腺受体至少表现出两种激素稳定型形态组合:一种"catecholamine"组合和一种"二次"组合.
虽然一些连接体会激活两种构造,从而导致双相反应,但它们的结构-活性关系尚不清楚.

研究的目的:

研究β1-上腺素受体连接体的结构-活性关系,它们通过甲基胺和二次形状组合作用.
为了识别与β1-adrenoceptor的二次构造相互作用的新型配体.

主要方法:

一个结构-活性假说是基于预测的连接体位置开发出来的.
通过对人类β1和β2上受体的放射性结和功能测定,评估了另外11个β1.
一种β1-上腺受体突变被用来确认二次构造的相互作用部位.

主要成果:

在11个案例中,在6个案例中,对二次形状的配体活性的预测是准确的.
确定了三种新型化合物,可诱导活性状态的二次构造.
一种CGP12177衍生物在甲基醇胺部位表现出对抗作用,并在二次部位表现出激活作用.
卡尔特洛洛和布尼特洛洛显示了双相度反应,激活了这两种形状.
布诺洛尔作为一个中性抗剂,缺乏二级位点激活.
突变分析证实TM4内部有一个共同的相互作用部位,用于诱导二次构造.

结论:

该研究确定了一个特定的相互作用部位,负责稳定替代β1-上腺受体构造.
发现了能够激活二次形状的新化合物.
这些发现为β1-adrenoceptor连接体设计提供了潜在的分子决定因素.

关键词:

亲密关系 (Affinity) 是一种关系.有效性有效性.分子建模分子建模分子药理学分子药理学第二个网站是二级网站.这是一个β1-adrenoceptor.

更多相关视频

Quantifying Agonist Activity at G Protein-coupled Receptors

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding

Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding

Published on: June 9, 2017

相关概念视频

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...

Adrenergic Receptors: β Subtype

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...

The Two-State Receptor Model

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...

Drug-Receptor Interaction: Agonist

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...

Adrenergic Receptors: ɑ Subtype

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...